WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention
Longer-Term MARIPOSA Results For J&J’s EGFR Drug Combo
Highlights will include data for Summit/Akeso’s PD-L1/VEGF bispecific versus Keytruda, ADCs and DLL3-targeting drugs for SCLC, and agents against EGFR, HER2 and Trop-2 in NSCLC.
